Department of Radiology, University of Washington, Seattle, Washington, USA.
Department of Medicine/Oncology, University of Washington, Seattle, Washington, USA.
J Magn Reson Imaging. 2018 Jul;48(1):226-236. doi: 10.1002/jmri.25909. Epub 2017 Nov 27.
Hormone receptor-positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed.
To evaluate the prognostic potential of diffusion-weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10-year recurrence risk.
Retrospective.
In all, 107 consecutive patients (from 2/2010 to 1/2013) with estrogen receptor (ER)-positive/HER2neu-negative invasive breast cancer who had the 21-gene recurrence score (RS) test (Oncotype DX, Genomic Health).
FIELD STRENGTH/SEQUENCE: Each subject underwent presurgical 3T breast MRI, which included DWI (b = 0, 800 s/mm ).
Apparent diffusion coefficient (ADC) and contrast-to-noise ratio (CNR) were measured for each lesion by a fifth year radiology resident. Pathological markers (Nottingham histologic grade, Ki-67, RS) were determined from pathology reports. Medical records were reviewed to assess recurrence-free survival.
RS was stratified into low (<18), moderate (18-30), and high (>30)-risk groups. Associations of DWI characteristics with pathologic biomarkers were evaluated by binary or ordinal logistic regression, as appropriate, with adjustment for multiple comparisons. Post-hoc comparisons between specific groups were also performed.
ADCmean (odds ratio [OR] = 0.61 per 1 standard deviation [SD] increase, adj. P = 0.044) and CNR (OR = 1.76 per 1-SD increase, adj. P = 0.026) were significantly associated with increasing tumor grade. DWI CNR was also significantly associated with a high (Ki-67 ≥14%) proliferation rate (OR = 2.55 per 1-SD increase, adj. P = 0.026). While there were no statistically significant linear associations in ADC (adj. P = 0.80-0.85) and CNR (adj. P = 0.56) across all three RS groups by ordinal logistic regression, post-hoc analyses suggested that high RS lesions exhibited lower ADCmean (P = 0.037) and ADCmax (P = 0.004) values and higher CNR (P = 0.008) compared to lesions with a low or moderate RS.
DWI characteristics correlated with tumor grade, proliferation index, and RS, and may potentially help to identify those with highest recurrence risk and most potential benefit from chemotherapy.
3 Technical Efficacy Stage 3 J. Magn. Reson. Imaging 2017.
激素受体阳性乳腺癌是最常见的亚型;需要更好的工具来识别这一组患者中哪些患者将从化疗中明显受益。
通过研究与病理生物标志物和基因组 10 年复发风险检测的相关性,评估扩散加权 MRI(DWI)的预后潜力。
回顾性。
共纳入 107 例连续患者(2010 年 2 月至 2013 年 1 月),雌激素受体(ER)阳性/HER2neu 阴性浸润性乳腺癌,均接受了 21 基因复发评分(RS)检测(Oncotype DX,基因组健康)。
磁场强度/序列:每位患者均在术前进行 3T 乳腺 MRI 检查,包括 DWI(b=0、800 s/mm )。
由一名第五年放射科住院医师对每个病变进行表观扩散系数(ADC)和对比噪声比(CNR)测量。病理标志物(诺丁汉组织学分级、Ki-67、RS)由病理报告确定。回顾医疗记录以评估无复发生存率。
RS 分为低(<18)、中(18-30)和高(>30)风险组。通过二元或有序逻辑回归评估 DWI 特征与病理生物标志物的相关性,适当调整多重比较。还进行了特定组之间的事后比较。
ADCmean(每增加 1 个标准差的比值比 [OR] = 0.61,调整后 P=0.044)和 CNR(每增加 1 个 SD 的 OR = 1.76,调整后 P=0.026)与肿瘤分级的升高显著相关。DWI CNR 也与高(Ki-67≥14%)增殖率显著相关(每增加 1 个 SD 的 OR = 2.55,调整后 P=0.026)。虽然通过有序逻辑回归没有发现 ADC(调整后 P=0.80-0.85)和 CNR(调整后 P=0.56)在所有三个 RS 组之间存在统计学上的线性关联,但事后分析表明,高 RS 病变的 ADCmean(P=0.037)和 ADCmax(P=0.004)值较低,CNR(P=0.008)值较高与低或中 RS 病变相比。
DWI 特征与肿瘤分级、增殖指数和 RS 相关,可能有助于识别那些复发风险最高、化疗获益最大的患者。
3 级技术疗效